Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.

Ismail Z, Peacock SJ, Kovacic L, Hoch JS.

Int J Technol Assess Health Care. 2017 Jan;33(4):481-486. doi: 10.1017/S0266462317000642. Epub 2017 Sep 5.

PMID:
28871898
2.
3.

Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?

Chim L, Kelly PJ, Salkeld G, Stockler MR.

Pharmacoeconomics. 2010;28(6):463-75. doi: 10.2165/11533000-000000000-00000. Erratum in: Pharmacoeconomics. 2011 Feb 1;29(2):171-2.

PMID:
20465315
4.

The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.

Yong JH, Beca J, Hoch JS.

Pharmacoeconomics. 2013 Mar;31(3):229-36. doi: 10.1007/s40273-012-0022-5.

PMID:
23322588
5.

Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.

Bentley C, Costa S, Burgess MM, Regier D, McTaggart-Cowan H, Peacock SJ.

BMC Health Serv Res. 2018 May 8;18(1):339. doi: 10.1186/s12913-018-3117-7.

6.

Possible Impact of Incremental Cost-Effectiveness Ratio (ICER) on Decision Making for Cancer Screening in Hong Kong: A Systematic Review.

Wong CK, Lang BH, Guo VY, Lam CL.

Appl Health Econ Health Policy. 2016 Dec;14(6):647-657. Review.

PMID:
27502943
7.

A Time-Trend Economic Analysis of Cancer Drug Trials.

Cressman S, Browman GP, Hoch JS, Kovacic L, Peacock SJ.

Oncologist. 2015 Jul;20(7):729-36. doi: 10.1634/theoncologist.2014-0437. Epub 2015 Jun 1.

8.

Using pharmacoeconomic analysis to make drug insurance coverage decisions.

Anis AH, Rahman T, Schechter MT.

Pharmacoeconomics. 1998 Jan;13(1 Pt 2):119-26.

PMID:
10176146
9.

Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.

Nosyk B, Min JE, Lima VD, Hogg RS, Montaner JS; STOP HIV/AIDS study group.

Lancet HIV. 2015 Sep;2(9):e393-400. doi: 10.1016/S2352-3018(15)00127-7. Epub 2015 Jul 16.

10.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group.

J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.

PMID:
19666851
11.

Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

MacLeod TE, Harris AH, Mahal A.

Patient. 2016 Jun;9(3):201-22. doi: 10.1007/s40271-015-0139-7. Review.

PMID:
26370257
12.

Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea-hypopnea in British Columbia.

Tan MC, Ayas NT, Mulgrew A, Cortes L, FitzGerald JM, Fleetham JA, Schulzer M, Ryan CF, Ghaeli R, Cooper P, Marra CA.

Can Respir J. 2008 Apr;15(3):159-65.

13.

Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.

Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ.

Value Health. 2010 Sep-Oct;13(6):703-11. doi: 10.1111/j.1524-4733.2010.00737.x. Epub 2010 Jun 7.

14.

Clinical effectiveness and cost-effectiveness of a multifaceted podiatry intervention for falls prevention in older people: a multicentre cohort randomised controlled trial (the REducing Falls with ORthoses and a Multifaceted podiatry intervention trial).

Cockayne S, Rodgers S, Green L, Fairhurst C, Adamson J, Scantlebury A, Corbacho B, Hewitt CE, Hicks K, Hull R, Keenan AM, Lamb SE, McIntosh C, Menz HB, Redmond A, Richardson Z, Vernon W, Watson J, Torgerson DJ.

Health Technol Assess. 2017 Apr;21(24):1-198. doi: 10.3310/hta21240.

15.

The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial.

Molassiotis A, Russell W, Hughes J, Breckons M, Lloyd-Williams M, Richardson J, Hulme C, Brearley S, Campbell M, Garrow A, Ryder W.

Health Technol Assess. 2013 Jun;17(26):1-114. doi: 10.3310/hta17260.

17.

Role of economic evidence in coverage decision-making in South Korea.

Bae EY, Kim HJ, Lee HJ, Jang J, Lee SM, Jung Y, Yoon N, Kim TK, Kim K, Yang BM.

PLoS One. 2018 Oct 24;13(10):e0206121. doi: 10.1371/journal.pone.0206121. eCollection 2018.

18.

Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.

Dvortsin E, Gout-Zwart J, Eijssen EL, van Brussel J, Postma MJ.

PLoS One. 2016 Jan 22;11(1):e0146551. doi: 10.1371/journal.pone.0146551. eCollection 2016. Review.

19.
20.

A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.

Leung L, de Lemos ML, Kovacic L.

J Oncol Pharm Pract. 2018 Dec;24(8):584-598. doi: 10.1177/1078155217722047. Epub 2017 Jul 26.

PMID:
28747103

Supplemental Content

Support Center